---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-056596"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-05-14T20:05:17+00:00"
generated_at: "2026-05-14T21:01:59.073297+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU

## Summary
- Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.
- Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.
- Jeet Mahal appointed CEO to lead next phase of clinical growth.
- Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.
- Median follow-up >200 days; KIT-related AEs low-grade and resolved on study.

## SEC filing metadata
- accession: 0001213900-26-056596
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-05-14T20:05:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/0001213900-26-056596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/ea0290792-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-056596
- JSON: https://secwatch.observer/filing/0001213900-26-056596.json
- Plain text: https://secwatch.observer/filing/0001213900-26-056596.txt

## Key facts
- Earnings Releases
  Jasper Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income net loss of $1.2 million, EPS basic and diluted net loss per share attributable to common stockholders of $0.04.
  - Period: the quarter ended March 31, 2026
  - Net income: net loss of $1.2 million
  - EPS: basic and diluted net loss per share attributable to common stockholders of $0.04
  - Result: reported results
  source text: Jasper reported a net loss of $1.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/0001213900-26-056596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.